Bariatric surgery as an important step towards kidney transplantation in patients with morbid obesity and chronic kidney disease

封面


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

An analysis of scientific studies devoted to the problem of bariatric surgery in patients with stages IIIb–V as chronic kidney disease (CKD) as the main step towardspossible kidney transplantation is presented. Obesity leads to CKD both directly, acting as an independent risk factor, and indirectly, by increasing the risk of diabetes, hypertension and atherosclerosis (i.e., a group of independent risk factors for CKD). CKD with an outcome of chronic renal failure is the second most common cause of mortality and disability in obese patients. In most kidney transplantation centers, a body mass index of more than 40 kg/m2 is a contraindication for to transplantation (refusal to be included on the waiting list); and a body mass index of more than 35 kg/m2 is a relative contraindication. In some cases, bariatric surgery is the only way to perform organ transplantation. Direct indications for bariatric surgery in patients with morbid obesity undergoing hemodialysis therapy have been identified. The established diet before/after bariatric surgery with the inclusion of protein isolate is not the cause of protein overload in patients with CKD. Bariatric surgery is considered a safe treatment option for obesity in potential kidney transplant candidates, given their continued need for immunosuppressive therapy.

全文:

受限制的访问

作者简介

Evgenia Voronets

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies

编辑信件的主要联系方式.
Email: zhenuaria@list.ru
ORCID iD: 0009-0003-5546-8671
俄罗斯联邦, Moscow

Alexander Smirnov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies

Email: alvsmirnov@mail.ru
ORCID iD: 0000-0003-3897-8306
SPIN 代码: 5619-1151

MD, Cand. Sci. (Medicine), Associate Professor

俄罗斯联邦, Moscow

Vladimir Stankevich

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies

Email: v-stankevich@yandex.ru
ORCID iD: 0000-0002-8620-8755
SPIN 代码: 5126-6092

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

Zaypulla Abdulkerimov

Russian University of Medicine

Email: dr-zay@yandex.ru
ORCID iD: 0000-0003-4555-5184
SPIN 代码: 7022-2259

MD, Cand. Sci. (Medicine)

俄罗斯联邦, Moscow

Dmitry Panchenkov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Russian University of Medicine

Email: dnpanchenkov@mail.ru
ORCID iD: 0000-0001-8539-4392
SPIN 代码: 4316-4651

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow; Moscow

Vladimir Sharobaro

Smolensk State Medical University

Email: sharobarovi1@mail.ru
ORCID iD: 0000-0003-1501-706X
SPIN 代码: 8529-5855

MD, Dr. Sci. (Medicine), Assistant Professor

俄罗斯联邦, Smolensk

Yury Ivanov

Federal Research and Clinical Center of Specialized Medical Care and Medical Technologies; Russian University of Medicine

Email: ivanovkb83@yandex.ru
ORCID iD: 0000-0001-6209-4194
SPIN 代码: 3240-4335

MD, Dr. Sci. (Medicine), Professor

俄罗斯联邦, Moscow; Moscow

参考

  1. Di Cesare M, Bentham J, Zhou B, et al. Trends in adult bodymass index in 200 countries from 1975 to 2014: a pooled analysis of 1698 population-based measurement studies with 19·2 million participants. Lancet. 2016;387(10026):1377–1396. doi: 10.1016/S0140-6736(16)30054-X EDN: WSVMWT Erratum in: Lancet. 2016;387(10032):1998. doi: 10.1016/S0140-6736(16)30472-X
  2. Rutkowski P, Klassen A, Sebekova K, et al. Renal disease in obesity: the need for greater attention. J Ren Nutr. 2006;16(3):216–223. doi: 10.1053/j.jrn.2006.04.017
  3. Kawai T, Autieri MV, Scalia R. Adipose tissue inflammation and metabolic dysfunction in obesity. Am J Physiol Cell Physiol. 2021;320(3):C375–C391. doi: 10.1152/ajpcell.00379.2020 EDN: KGYKVH
  4. Hall JE, do Carmo JM, da Silva AA, et al. Obesity, kidney dysfunction and hypertension: mechanistic links. Nat Rev Nephrol. 2019;15(6):367–385. doi: 10.1038/s41581-019-0145-4 EDN: UIPTZA
  5. Czaja-Stolc S, Potrykus M, Stankiewicz M, et al. Pro-inflammatory profile of adipokines in obesity contributes to pathogenesis, nutritional disorders, and cardiovascular risk in chronic kidney disease. Nutrients. 2022;14(7):1457. doi: 10.3390/nu14071457 EDN: USBZEK
  6. Martin-Taboada M, Vila-Bedmar R, Medina-Gómez G. From obesity to chronic kidney disease: how can adipose tissue affect renal function? Nephron. 2021;145(6):609–613. doi: 10.1159/000515418 EDN: NXFKTR
  7. Garofalo C, Borrelli S, Minutolo R, et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224–1235. doi: 10.1016/j.kint.2016.12.013 EDN: YXQYCZ
  8. Panwar B, Hanks LJ, Tanner RM, et al. Obesity, metabolic health, and the risk of end-stage renal disease. Kidney Int. 2015;87(6):1216–1222. doi: 10.1038/ki.2014.384
  9. Jung CH, Lee MJ, Kang YM, et al. The risk of chronic kidney disease in a metabolically healthy obese population. Kidney Int. 2015;88(4):843–850. doi: 10.1038/ki.2015.183
  10. Hsu CY, McCulloch CE, Iribarren C, et al. Body mass index and risk for end-stage renal disease. Ann Intern Med. 2006;144(1):21–28. doi: 10.7326/0003-4819-144-1-200601030-00006
  11. Hojs R, Ekart R, Bevc S, Vodošek Hojs N. Chronic kidney disease and obesity. Nephron. 2023;147(11):660–664. doi: 10.1159/000531379 EDN: GTILBX
  12. Ogden CL, Carroll MD, Flegal KM. Epidemiologic trends in overweight and obesity. Endocrinol Metab Clin North Am. 2003;32(4):741–vii. doi: 10.1016/s0889-8529(03)00074-4
  13. Jiang Z, Wang Y, Zhao X, et al. Obesity and chronic kidney disease. Am J Physiol Endocrinol Metab. 2023;324(1):E24–E41. doi: 10.1152/ajpendo.00179.2022 EDN: MJNLDS
  14. Martínez-Montoro JI, Morales E, Cornejo-Pareja I, et al. Obesity-related glomerulopathy: Current approaches and future perspectives. Obes Rev. 2022;23(7):e13450. doi: 10.1111/obr.13450 EDN: AWTVBA
  15. Blüher M. Obesity: global epidemiology and pathogenesis. Nat Rev Endocrinol. 2019;15(5):288–298. doi: 10.1038/s41574-019-0176-8 EDN: PYTWYS
  16. Wang Y, Chen X, Song Y, et al. Association between obesity and kidney disease: a systematic review and meta-analysis. Kidney Int. 2008;73(1):19–33. doi: 10.1038/sj.ki.5002586
  17. D'Agati VD, Chagnac A, de Vries AP, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016;12(8):453–471. doi: 10.1038/nrneph.2016.75 EDN: WRLYVT
  18. Henegar JR, Bigler SA, Henegar LK, et al. Functional and structural changes in the kidney in the early stages of obesity. J Am Soc Nephrol. 2001;12(6):1211–1217. doi: 10.1681/ASN.V1261211
  19. Dudley C, Harden P. Renal Association Clinical Practice Guideline on the assessment of the potential kidney transplant recipient. Nephron Clin Pract. 2011;118 Suppl. 1:c209–c224. doi: 10.1159/000328070
  20. Segev DL, Simpkins CE, Thompson RE, et al. Obesity impacts access to kidney transplantation. J Am Soc Nephrol. 2008;19(2):349–355. doi: 10.1681/ASN.2007050610
  21. Gore JL, Pham PT, Danovitch GM, et al. Obesity and outcome following renal transplantation. Am J Transplant. 2006;6(2):357–363. doi: 10.1111/j.1600-6143.2005.01198.x
  22. Chang JH, Mushailov V, Mohan S. Obesity and kidney transplantation. Curr Opin Organ Transplant. 2023;28(2):149–155. doi: 10.1097/MOT.0000000000001050 EDN: HBKUOY
  23. Hill CJ, Courtney AE, Cardwell CR, et al. Recipient obesity and outcomes after kidney transplantation: a systematic review and meta-analysis. Nephrol Dial Transplant. 2015;30(8):1403–1411. doi: 10.1093/ndt/gfv214
  24. Chadban SJ, Ahn C, Axelrod DA, et al. KDIGO clinical practice guideline on the evaluation and management of candidates for kidney transplantation. Transplantation. 2020;104(4S1 Suppl. 1):S11–S103. doi: 10.1097/TP.0000000000003136 EDN: IOHQKX
  25. Clinical guidelines. Living kidney donation. Russian Transplantation Society; 2023.
  26. Zharikov AA, Saydulaev DA, Sadovnikov SV, Miloserdov IA. Efficacy of surgical techniques for morbid obesity and their potentials in end-stage renal disease in preparation for kidney transplantation. Russian Journal of Transplantology and Artificial Organs. 2022;24(2):125–133. doi: 10.15825/1995-1191-2022-2-125-133 EDN: ZJSHAX
  27. Fischer H, Weiss RE, Friedman AN, et al. The relationship between kidney function and body mass index before and after bariatric surgery in patients with chronic kidney disease. Surg Obes Relat Dis. 2021;17(3):508–515. doi: 10.1016/j.soard.2020.11.010 EDN: ZHTGLQ
  28. Chang AR, Grams ME, Navaneethan SD. Bariatric surgery and kidney-related outcomes. Kidney Int Rep. 2017;2(2):261–270. doi: 10.1016/j.ekir.2017.01.010 EDN: YHMSYH
  29. Coleman KJ, Shu YH, Fischer H, et al. Bariatric surgery and risk of death in persons with chronic kidney disease. Ann Surg. 2022;276(6):e784–e791. doi: 10.1097/SLA.0000000000004851 EDN: CPHUUD
  30. Pané A, Claro M, Molina-Andujar A, et al. Bariatric surgery outcomes in patients with chronic kidney disease. J Clin Med. 2023;12(18):6095. doi: 10.3390/jcm12186095 EDN: XKPZHB
  31. Friedman AN, Cohen RV. Bariatric surgery as a renoprotective intervention. Curr Opin Nephrol Hypertens. 2019;28(6):537–544. doi: 10.1097/MNH.0000000000000539
  32. Holcomb CN, Goss LE, Almehmi A, et al. Bariatric surgery is associated with renal function improvement. Surg Endosc. 2018;32(1):276–281. doi: 10.1007/s00464-017-5674-y EDN: FWNPLP
  33. Imam TH, Coleman KJ. Obesity and mortality in end-stage renal disease. is it time to reverse the "reverse epidemiology" — at least in peritoneal dialysis? J Ren Nutr. 2019;29(4):269–275. doi: 10.1053/j.jrn.2018.09.005
  34. Fried M, Yumuk V, Oppert JM, et al. Interdisciplinary European guidelines on metabolic and bariatric surgery. Obes Surg. 2014;24(1):42–55. doi: 10.1007/s11695-013-1079-8 EDN: SKLLDB
  35. Stankevich VR, Ivanov YuV, Sharobaro VI, et al. Surgical treatment of morbid obesity. Moscow: Redprint; 2021. 292 p. (In Russ.)
  36. Clinical recommendations. Chronic kidney disease (CKD). Association of nephrologists. Approved by the Scientific and Practical Council of the Ministry of Health of the Russian Federation. 2021.
  37. Kostro JZ, Bzoma B, Proczko-Stepaniak M, et al. Kidney transplantation in patients after bariatric surgery: high-volume bariatric and transplant center experience. Transplant Proc. 2022;54(4):955–959. doi: 10.1016/j.transproceed.2022.03.014 EDN: ULNUPK
  38. Padwal R, Brocks D, Sharma AM. A systematic review of drug absorption following bariatric surgery and its theoretical implications. Obes Rev. 2010;11(1):41–50. doi: 10.1111/j.1467-789X.2009.00614.x
  39. Cheymol G. Effects of obesity on pharmacokinetics implications for drug therapy. Clin Pharmacokinet. 2000;39(3):215–231. doi: 10.2165/00003088-200039030-00004 EDN: XWGENS
  40. Marterre WF, Hariharan S, First MR, Alexander JW. Gastric bypass in morbidly obese kidney transplant recipients. Clin Transplant. 1996;10(5):414–419.
  41. Rogers CC, Alloway RR, Alexander JW, et al. Pharmacokinetics of mycophenolic acid, tacrolimus and sirolimus after gastric bypass surgery in end-stage renal disease and transplant patients: a pilot study. Clin Transplant. 2008;22(3):281–291. doi: 10.1111/j.1399-0012.2007.00783.x
  42. Gheith O, Al-Otaibi T, Halim MA, et al. Bariatric surgery in renal transplant patients. Exp Clin Transplant. 2017;15(Suppl. 1):164–169. doi: 10.6002/ect.mesot2016.P35
  43. Hardinger KL, Park JM, Schnitzler MA, et al. Pharmacokinetics of tacrolimus in kidney transplant recipients: twice daily versus once daily dosing. Am J Transplant. 2004;4(4):621–625. doi: 10.1111/j.1600-6143.2004.00383.x
  44. Baraldo M, Furlanut M. Chronopharmacokinetics of ciclosporin and tacrolimus. Clin Pharmacokinet. 2006;45(8):775–788. doi: 10.2165/00003088-200645080-00002 EDN: BHMERZ
  45. Tan SYT, Lee PC, Ganguly S, et al. Bariatric Surgery in kidney transplant candidates and recipients: experience at an Asian center. J Obes Metab Syndr. 2022;31(4):325–333. doi: 10.7570/jomes21090 EDN: GGQKYN
  46. Maroun J, Vahibe A, Shah M, et al. Impact of chronic immunosuppression on short-, mid-, and long-term bariatric surgery outcomes. Obes Surg. 2023;33(1):240–246. doi: 10.1007/s11695-022-06372-7 EDN: QZIVBI
  47. Reding R, Michel LA, Donckier J, et al. Surgery in patients on long-term steroid therapy: a tentative model for risk assessment. Br J Surg. 1990;77(10):1175–1178. doi: 10.1002/bjs.1800771028
  48. Hoogeveen EK, Aalten J, Rothman KJ, et al. Effect of obesity on the outcome of kidney transplantation: a 20-year follow-up. Transplantation. 2011;91(8):869–874. doi: 10.1097/TP.0b013e3182100f3a
  49. Yemini R, Nesher E, Carmeli I, et al. Bariatric surgery is efficacious and improves access to transplantation for morbidly obese renal transplant candidates. Obes Surg. 2019;29(8):2373–2380. doi: 10.1007/s11695-019-03925-1 EDN: GWRSAA
  50. Cohen JB, Lim MA, Tewksbury CM, et al. Bariatric surgery before and after kidney transplantation: long-term weight loss and allograft outcomes. Surg Obes Relat Dis. 2019;15(6):935–941. doi: 10.1016/j.soard.2019.04.002

补充文件

附件文件
动作
1. JATS XML
2. Fig. 1. Possible variants of the course of chronic kidney disease after bariatric surgery. Adopted from [30] with permission of copyright holder. © A. Pané et al., 2023.

下载 (125KB)

版权所有 © Eco-Vector, 2025

许可 URL: https://eco-vector.com/for_authors.php#07

СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия  ПИ № ФС 77 - 86296 от 11.12.2023 г
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ЭЛ № ФС 77 - 80632 от 15.03.2021 г
.